NASDAQ: BRKRBruker Corp Stock
$64.54+0.81 (+1.27%)
Updated Oct 11, 2024
BRKR Price
$64.54
Fair Value Price
$40.89
Market Cap
$9.77B
52 Week Low
$53.79
52 Week High
$94.86
P/E
26.78x
P/B
5.46x
P/S
3.02x
PEG
2.24x
Dividend Yield
0.31%
Revenue
$3.12B
Earnings
$352.10M
Gross Margin
49.7%
Operating Margin
14.61%
Profit Margin
11.3%
Debt to Equity
2.28
Operating Cash Flow
$273M
Beta
1.09
Next Earnings
Oct 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BRKR Overview
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BRKR scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BRKR ($64.54) is overvalued by 57.85% relative to our estimate of its Fair Value price of $40.89 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BRKR ($64.54) is not significantly undervalued (57.85%) relative to our estimate of its Fair Value price of $40.89 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BRKR ($64.54) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more BRKR due diligence checks available for Premium users.
Be the first to know about important BRKR news, forecast changes, insider trades & much more!
BRKR News
Valuation
BRKR fair value
Fair Value of BRKR stock based on Discounted Cash Flow (DCF)
Price
$64.54
Fair Value
$40.89
Overvalued by
57.85%
BRKR ($64.54) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BRKR ($64.54) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BRKR ($64.54) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BRKR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
26.78x
Industry
42.12x
Market
27.31x
BRKR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BRKR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
BRKR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.46x
Industry
4.07x
BRKR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BRKR price to earnings growth (PEG)
For valuing profitable companies with growth potential
BRKR is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
BRKR's financial health
Profit margin
Revenue
$800.7M
Net Income
$7.6M
Profit Margin
0.9%
BRKR's Earnings (EBIT) of $455.90M... subscribe to Premium to read more.
Interest Coverage Financials
BRKR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.9B
Liabilities
$4.1B
Debt to equity
2.28
BRKR's short-term assets ($2.15B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BRKR's long-term liabilities ($2.77B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BRKR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BRKR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.1M
Investing
-$1.3B
Financing
$1.2B
BRKR's operating cash flow ($272.50M)... subscribe to Premium to read more.
Debt Coverage Financials
BRKR vs Medical Device Stocks
Bruker Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.